Carol Hitchman
Counsel
Carol has been involved in cases relating to basic compound patents, formulation patents and use patents and has been involved extensively in litigation relating to trademarks for the appearance of pharmaceuticals. Carol has written numerous papers and given presentations for the Intellectual Property Institute of Canada (IPIC), the Law Society of Upper Canada and the Canadian Bar Association, including presentations to Federal Court judges and prothonotaries. Carol has taught Patent Agent Tutorials for IPIC as well as the IPIC’s McGill Patents course.
Education
- B.A., University of Toronto
- LL.B., Osgoode Hall Law School
Bar Admission
- Ontario, 1984
Recognition
- "Very experienced and knowledgable patent litigator, highly sought after across a broad range of industries for her expertise in IP law." – WWL, 2021
My recent cases
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,652,442 and 2,771,403 (lenvatinib).
Actions under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,450,740, No. 2,529,400 and No. 2,536,251 as well as patent infringement actions relating to Patent No. 2,518,435 with respect to products containing sitagliptin and products containing both sitagliptin and metformin.
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,682,598 with respect to products containing sapropterin.
Action for copyright infringement. Acting as counsel on motions relating to the Statement of Claim and appeals therefrom.
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,752,550 (pomalidomide)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,794,060 (pomalidomide)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,791,171 (apixaban)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,461,202 (apixaban)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,344,318 and 2,743,326 (daptomycin)
Patent infringement regarding Patent No. 2,743,326 (daptomycin)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,507,002 and 2,496,780 (silodosin)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban)
CIRA domain name dispute relating to the domain name STRIPMEISTER.CA
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,477,301, 2,688,709, 2,476,983, 2,688,694, 2,537,092, 2,687,927, 2,688,695, 2,741,575, 2,688,708, 2,687,924 and 2,741,412 (lenalidomide)
Application under s. 18.1 of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,586,023 (sevelamer)
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), 157,162 (ENERGIZER) and 740,338 (ENERGIZER)
Patent infringement case regarding Patent No. 2,355,347 (quinapril)
Patent infringement case regarding Patent No. 1,336,777 (clopidogrel).
Patent infringement case regarding Patent No. 1,336,777 (clopidogrel).